BioAscent Email Format
Biotechnology ResearchScotland, United Kingdom51-200 Employees
BioAscent, founded in 2013, provides integrated drug discovery services designed to move compounds from concept toward preclinical development. Based at the former Organon/MSD R&D site in Newhouse, Scotland, it offers capabilities spanning assay development, target analysis, screening strategies, compound screening, medicinal and synthetic chemistry, computational chemistry, and compound management, with access to in-house diversity and fragment libraries. Its team has experience advancing projects from assay development through preclinical and clinical candidates across multiple target classes and therapeutic areas. The company serves pharmaceutical and biotech customers seeking comprehensive discovery solutions, including management of large compound libraries for clients in liquid and solid formats. Recent developments include a November 2025 collaboration with Keltic Pharma to provide access to a peptide discovery platform for GPCR targets.